Better Therapeutics (NASDAQ:BTTX) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 24.07 percent increase over losses of $(0.54) per share from the same period last year.
Wells Fargo Maintains Equal-Weight on Blackstone, Raises Price Target to $122
Wells Fargo analyst Finian O'Shea maintains Blackstone (NYSE:BX) with a Equal-Weight and raises the price target from $120 to $122.